UA78104C2 - Benzenesulfonate salts of 4-fluoro-2-cyanopyrrolidine derivatives - Google Patents

Benzenesulfonate salts of 4-fluoro-2-cyanopyrrolidine derivatives Download PDF

Info

Publication number
UA78104C2
UA78104C2 UAA200502704A UA2005002704A UA78104C2 UA 78104 C2 UA78104 C2 UA 78104C2 UA A200502704 A UAA200502704 A UA A200502704A UA 2005002704 A UA2005002704 A UA 2005002704A UA 78104 C2 UA78104 C2 UA 78104C2
Authority
UA
Ukraine
Prior art keywords
fluoro
compound
cyano
ethylamino
hydroxy
Prior art date
Application number
UAA200502704A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of UA78104C2 publication Critical patent/UA78104C2/uk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
UAA200502704A 2002-08-29 2003-08-27 Benzenesulfonate salts of 4-fluoro-2-cyanopyrrolidine derivatives UA78104C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002249821 2002-08-29
PCT/JP2003/010828 WO2004020407A1 (ja) 2002-08-29 2003-08-27 4−フルオロ−2−シアノピロリジン誘導体ベンゼンスルホン酸塩

Publications (1)

Publication Number Publication Date
UA78104C2 true UA78104C2 (en) 2007-02-15

Family

ID=31972599

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200502704A UA78104C2 (en) 2002-08-29 2003-08-27 Benzenesulfonate salts of 4-fluoro-2-cyanopyrrolidine derivatives

Country Status (19)

Country Link
US (1) US7304166B2 (ru)
EP (1) EP1535907A4 (ru)
JP (1) JP3746063B2 (ru)
KR (1) KR100582141B1 (ru)
CN (1) CN1310885C (ru)
AU (1) AU2003261748B2 (ru)
BR (1) BR0313831A (ru)
CA (1) CA2496623C (ru)
EA (1) EA007613B1 (ru)
EC (1) ECSP055708A (ru)
HK (1) HK1082497A1 (ru)
HR (1) HRP20050205A2 (ru)
MX (1) MXPA05002253A (ru)
NO (1) NO20050867L (ru)
NZ (1) NZ538956A (ru)
PL (1) PL374664A1 (ru)
UA (1) UA78104C2 (ru)
WO (1) WO2004020407A1 (ru)
ZA (1) ZA200501418B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
WO2006080401A1 (ja) 2005-01-27 2006-08-03 Mitsui Chemicals, Inc. フッ素化プロリン誘導体の製造方法
JP2008024592A (ja) * 2005-01-28 2008-02-07 Taisho Pharmaceut Co Ltd シアノピロリジン誘導体含有固形製剤用組成物、それを含有する固形製剤及びその製造方法
MX2007011546A (es) * 2005-03-22 2007-10-19 Hoffmann La Roche Nueva sal y polimorfos del inhibidor de dipeptidil-peptidasa iv.
JP5027137B2 (ja) 2005-09-14 2012-09-19 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤の投与
KR101368988B1 (ko) 2005-09-16 2014-02-28 다케다 야쿠힌 고교 가부시키가이샤 디펩티딜 펩티다제 억제제
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8927504B2 (en) 2007-04-03 2015-01-06 Mitsubishi Tanabe Pharma Corporation Combined use of dipeptidyl peptidase 4 inhibitor and sweetener
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
JP2013523819A (ja) 2010-04-06 2013-06-17 アリーナ ファーマシューティカルズ, インコーポレイテッド Gpr119レセプターのモジュレーターおよびそれに関連する障害の処置
WO2012040279A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
WO2016144862A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
EP3606527A1 (en) 2017-04-03 2020-02-12 Coherus Biosciences, Inc. Ppar-gamma agonist for treatment of progressive supranuclear palsy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4432987A (en) 1982-04-23 1984-02-21 Pfizer Inc. Crystalline benzenesulfonate salts of sultamicillin
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
TW492957B (en) * 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
TW486475B (en) 1996-12-26 2002-05-11 Ube Industries Acid addition salt of optically active piperidine compound and process for preparing the same
JP3107784B2 (ja) 1996-12-26 2000-11-13 宇部興産株式会社 光学活性ピペリジン誘導体の酸付加塩及びその製法
US6252063B1 (en) 1998-12-01 2001-06-26 Merck & Co., Inc. Crystalline salts of a carbapenem antibiotic
TWI243162B (en) * 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives

Also Published As

Publication number Publication date
HRP20050205A2 (en) 2005-10-31
KR20050059094A (ko) 2005-06-17
CA2496623A1 (en) 2004-03-11
CA2496623C (en) 2008-02-12
BR0313831A (pt) 2005-07-05
JP3746063B2 (ja) 2006-02-15
US20060106087A1 (en) 2006-05-18
KR100582141B1 (ko) 2006-05-22
MXPA05002253A (es) 2005-06-08
PL374664A1 (en) 2005-10-31
JPWO2004020407A1 (ja) 2005-12-15
EA007613B1 (ru) 2006-12-29
EP1535907A1 (en) 2005-06-01
HK1082497A1 (en) 2006-06-09
AU2003261748A1 (en) 2004-03-19
US7304166B2 (en) 2007-12-04
CN1310885C (zh) 2007-04-18
AU2003261748B2 (en) 2006-11-23
ZA200501418B (en) 2006-10-25
WO2004020407A1 (ja) 2004-03-11
CN1678575A (zh) 2005-10-05
ECSP055708A (es) 2005-08-11
EA200500420A1 (ru) 2005-08-25
EP1535907A4 (en) 2006-11-29
NO20050867L (no) 2005-02-18
NZ538956A (en) 2006-08-31

Similar Documents

Publication Publication Date Title
UA78104C2 (en) Benzenesulfonate salts of 4-fluoro-2-cyanopyrrolidine derivatives
EP2244712B1 (en) In vivo studies of crystalline forms of meloxicam
CN102421438B (zh) 乙酰水杨酸和茶氨酸的水溶性共结晶体的静脉制剂
US20060189682A1 (en) Water soluble prodrugs of COX-2 inhibitors
HUE026820T2 (en) The use of Syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders
CN105555783A (zh) 包含杂芳族环-苄基-酰胺-环核心的自分泌运动因子抑制剂
SK2612002A3 (en) Pharmaceutical formulation containing benzamide derivative with improved solubility and oral absorptivity
JP2020533396A (ja) Gsk1278863の結晶形及びその製造方法並びに医薬用途
EP3495352A1 (en) Crystal form of androgen receptor antagonist medication, preparation method therefor, and use
WO2023138662A9 (zh) 苯并嘧啶类化合物及其应用
EP1311506B1 (en) Chiral fluoroquinolizinone arginine salt forms
CN104884455A (zh) 丙型肝炎病毒抑制剂
JP2020505355A (ja) Gft−505の結晶形及びその製造方法並びに用途
CN115052868A (zh) 大麻素硫酸酯、及其盐和用途
KR20040079936A (ko) 염기성 아미노산 ii를 함유하는 o-아세틸살리실산의안정한 염
SK7832001A3 (en) Diazepinoindoles for treating chronic obstruction bronchopulmonary disease
JP3865698B2 (ja) 医薬組成物
TWI808217B (zh) 稠合三環γ-胺基酸衍生物之組合物及其製備方法
RU2681932C2 (ru) Фармацевтическая композиция, содержащая 5-{ 4-(аминосульфонил) фенил} -2,2-диметил-4-(3-фторфенил)-3(2н)-фуранон, и состав в капсулах, содержащий фармацевтическую композицию
JP4441477B2 (ja) 医薬組成物
US6784315B2 (en) Stilbene derivative crystal and method for producing the same
Mude Resolving Solubility Problems and Providing an Overview of Excipients to Boost Oral Drug Bioavailability
RU2766288C2 (ru) Аморфная форма 4-{ 4-[({ [4-хлор-3-(трифторметил)фенил]амино} карбонил)-амино]фенокси} -n-метилпиридин-2-карбоксамида тозилата (варианты), способ её получения и применение для лечения онкологических заболеваний
JP2005272457A (ja) シアノピロリジン誘導体を有効成分として含有する医薬
JP2005533075A (ja) 安定化された医薬製剤の一酸化窒素シンターゼ阻害剤(2s)−2−アミノ−4−[2−(エタンイミドイルアミノ)エチル]チオブタン酸